10-Q: EyePoint Pharmaceuticals Reports Increased Losses Amid Phase 3 DURAVYU Trials

EyePoint Pharmaceuticals reported a significant increase in net loss for Q3 2025 and the nine months ended September 30, 2025, driven by accelerated R&D for its lead candidate DURAVYU, while securing a $162.1 million equity financing to extend its cash runway into Q4 2027.

Summary

• Net loss for the three months ended September 30, 2025, increased by 103% to $59.7 million, compared to $29.4 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased by 84% to $164.4 million, compared to $89.5 million for the same period in 2024.
• Total revenues for the three months ended September 30, 2025, decreased by 91% to $1.0 million, primarily due to the recognition of deferred revenue in Q2 2025 and termination of certain agreements.
• Total revenues for the nine months ended September 30, 2025, decreased by 3% to $30.8 million, with a significant increase in royalty income due to the recognition of remaining deferred SWK royalty revenue.
• Research and development expenses surged by 62% to $47.8 million for the three months and 81% to $161.8 million for the nine months ended September 30, 2025, mainly due to ongoing DURAVYU Phase 3 clinical trials.
• Cash, cash equivalents, and marketable securities stood at $204.0 million as of September 30, 2025.
• The company completed an equity financing in October 2025, raising approximately $162.1 million in net proceeds, extending its cash runway into the fourth quarter of 2027.
• Enrollment was completed in the pivotal Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet age-related macular degeneration (wet AMD) on May 27, 2025, and July 29, 2025, respectively.
• Pivotal Phase 3 clinical trials (COMO and CAPRI) for DURAVYU in diabetic macular edema (DME) are expected to dose patients in the first quarter of 2026.
• New preclinical data for vorolanib, the active drug in DURAVYU, demonstrates inhibition of interleukin-6 (IL-6) mediated inflammation through JAK-1, positioning it as a potential multi-mechanism of action treatment.

Sentiment

Score: 6

Explanation: While financial losses increased significantly and revenues declined, these are largely attributable to heavy R&D investment in a promising lead candidate (DURAVYU) and one-time revenue recognition events. The completion of Phase 3 enrollment for wet AMD and new preclinical data are strong positive clinical developments. The successful capital raise significantly extends the cash runway, mitigating immediate liquidity concerns. The ongoing DOJ subpoena is a negative, but management believes it will not be material. The overall sentiment is cautiously optimistic, reflecting the high-risk, high-reward nature of late-stage biotech development.

Positives

• Enrollment completed for pivotal Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet AMD on May 27, 2025, and July 29, 2025, respectively, with data readout expected mid-2026.
• New preclinical data for DURAVYU's active drug, vorolanib, shows inhibition of IL-6 mediated inflammation through JAK-1, suggesting a multi-mechanism of action and reinforcing early clinical improvements.
• Successful completion of an equity financing in October 2025, raising approximately $162.1 million in net proceeds, which is expected to fund operations into Q4 2027, beyond anticipated Phase 3 wet AMD topline data.
• Progress in establishing a cGMP-compliant commercial manufacturing facility in Northbridge, Massachusetts, to support DURAVYU clinical supply and commercial readiness.

Negatives

• Net loss significantly increased by 103% to $59.7 million for the three months ended September 30, 2025, compared to $29.4 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased by 84% to $164.4 million, compared to $89.5 million in the prior year period.
• Total revenues for the three months ended September 30, 2025, decreased by 91% to $1.0 million, primarily due to the recognition of remaining deferred revenue from a 2023 license agreement and the termination of the ANI commercial supply agreement.
• Product sales, net, decreased by 12% for the three months and 46% for the nine months ended September 30, 2025, primarily due to the termination of the ANI commercial supply agreement.
• Interest and other income, net, decreased by 32% for the three months and 21% for the nine months ended September 30, 2025, driven by lower cash available for investment and a general decrease in market interest rates.
• The company has a history of operating losses and expects to continue incurring substantial additional operating losses for at least the next several years.
• Accrued a $4.7 million contingent liability for a possible settlement related to a U.S. Department of Justice subpoena concerning sales, marketing, and promotional practices for DEXYCU.

Risks

• The timing, progress, and results of clinical development activities, including DURAVYU, are uncertain.
• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for DURAVYU.
• The sufficiency of existing cash resources and the ability to obtain additional capital on acceptable terms.
• Clinical trial results may not be predictive of future results, and interim/preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data observed during clinical trials could impact product development.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could affect regulatory processes.
• Changes in the regulatory and legislative environment, as well as U.S. and international trade policies, could impact operations.
• The duration, scope, and outcome of the U.S. Department of Justice (DOJ) subpoena and the ability to reach a negotiated resolution that will not materially impact the business.
• Dependence on contract research organizations, vendors, and clinical investigators for development activities.
• Ability to manufacture clinical and commercial supply of product candidates, including YUTIQ and DEXYCU for Ocumension Agreement.
• Impact of global economic conditions, geopolitical violence, unrest, and public health crises on the business and medical community.
• Market acceptance of product candidates, if approved, is not guaranteed.
• Ability to obtain and adequately maintain sufficient intellectual property protection and avoid infringement claims.
• Ability to implement corrective and preventive actions required by the FDA Warning Letter pertaining to YUTIQ manufacturing to the satisfaction of the FDA.
• Potential product liability claims.

Future Outlook

The company anticipates continued operating losses and significant cash outflows as it advances its product candidates, particularly DURAVYU, through clinical trials and towards potential commercialization. It expects to fund operations into the fourth quarter of 2027, beyond the anticipated Phase 3 wet AMD topline data for DURAVYU in 2026, utilizing its current cash and the net proceeds from the October 2025 equity financing. The company will continue to assess funding requirements and expects to seek additional capital in the future, acknowledging that such funding may not be available on favorable terms or at all.

Management Comments

• Management believes that the cash, cash equivalents, and investments in marketable securities of $204.0 million at September 30, 2025, along with the net proceeds of approximately $162.1 million from the October 2025 equity financing, will enable the company to fund operations into the fourth quarter of 2027, beyond Phase 3 wet AMD topline data for DURAVYU expected in 2026.
• Management believes that any negotiated resolution of the U.S. Department of Justice subpoena matter would not be material to the company's business or financial condition, based on discussions to date.

Industry Context

EyePoint Pharmaceuticals operates in the highly competitive and capital-intensive ophthalmic therapeutics market, focusing on sustained intraocular drug delivery for serious retinal diseases like wet AMD and DME. The significant increase in R&D expenses reflects the industry trend of substantial investment required for late-stage clinical development of novel therapies. The focus on a multi-mechanism of action for DURAVYU, combining TKI with Durasert E technology, positions it against existing anti-VEGF treatments and other investigational sustained-release therapies. The successful capital raise is critical in this environment to sustain long development cycles, while the ongoing DOJ inquiry highlights the regulatory scrutiny faced by pharmaceutical companies regarding sales and marketing practices.

Comparison to Industry Standards

• The company's R&D spend of $161.8 million for the nine months ended September 30, 2025, represents a substantial investment for a company of its size, reflecting the high costs associated with running multiple pivotal Phase 3 clinical trials for a lead candidate like DURAVYU. This level of investment is comparable to other clinical-stage biopharmaceutical companies advancing novel therapies in large indications.
• The cash runway extended into Q4 2027, following the $162.1 million capital raise, provides a reasonable timeframe for a clinical-stage biotech, especially with key Phase 3 data readouts expected in mid-2026. This is generally considered a positive for investor confidence, as it reduces immediate financing risk compared to companies with shorter runways.
• The significant net loss is typical for a biopharmaceutical company in late-stage clinical development, where R&D expenses far outweigh limited product revenues prior to market approval and commercialization. This financial profile is common among peers focused on bringing innovative, high-potential therapies to market.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a subpoena from the U.S. Attorneys Office for the District of Massachusetts (DOJ) in August 2022, seeking documents related to sales, marketing, and promotional practices for DEXYCU (commercialized 2019-2023).
• The company is cooperating fully with the government and is in discussions regarding a possible negotiated resolution.
• An accrual of $4.7 million has been recorded as of September 30, 2025, for the possible settlement of the DOJ investigation, plus additional legal expenses.
• Management believes any negotiated resolution would not be material to the company's business or financial condition, but there is no guarantee of reaching a final agreement.

Related Party Transactions

• Nancy S. Lurker, former CEO and current Vice Chair of the Board, is a board member of Altasciences, the parent company of Calvert Laboratories, Inc. (Calvert Labs), with which the company conducts business.
• The company recorded $0.1 million and $0.7 million of research and development expense for the three and nine months ended September 30, 2025, respectively, related to preclinical and analytical services provided by Altasciences.
• As of September 30, 2025, the company had accounts payable of $0.3 million and prepaid expenses of $0.4 million related to services provided by Altasciences.

Stakeholder Impact

• **Shareholders:** Experience significant dilution from the recent equity financing, but the extended cash runway reduces immediate financing risk. Increased R&D spend and net losses impact profitability, but clinical progress for DURAVYU offers potential long-term value. The DOJ subpoena introduces regulatory uncertainty.
• **Employees:** Continued investment in R&D and manufacturing facilities suggests job stability and growth opportunities, particularly in clinical development and manufacturing roles. Stock-based compensation remains a significant component of overall compensation.
• **Customers (future):** Potential for new, sustained-delivery treatments for wet AMD and DME (DURAVYU) could offer improved patient outcomes and convenience.
• **Creditors:** The recent capital raise improves the company's liquidity position, reducing short-to-medium term credit risk.
• **Regulatory Authorities:** The company is actively engaged with the FDA for DURAVYU's approval pathway and is cooperating with the DOJ regarding the subpoena, indicating adherence to regulatory processes and addressing compliance issues.

Next Steps

• Data readout for DURAVYU Phase 3 pivotal trials (LUGANO and LUCIA) for wet AMD beginning in mid-2026.
• First patient dosing in pivotal Phase 3 clinical trials (COMO and CAPRI) for DURAVYU in diabetic macular edema (DME) expected in the first quarter of 2026.
• Continue to assess cash and cash equivalents and future funding requirements, with an expectation to seek additional funding.
• Ongoing discussions with the U.S. Department of Justice regarding a possible negotiated resolution of the subpoena matter.
• Continue scale-up of the Northbridge commercial manufacturing facility to support DURAVYU clinical supply and commercial readiness.
• Monitor future guidance related to the One Big Beautiful Bill Act (OBBBA) and evaluate the impact of ASU 2023-09 and ASU 2024-03 on financial statement disclosures.

Key Dates

Recommendation

EyePoint Pharmaceuticals is in a critical, high-investment phase with its lead candidate DURAVYU. While the significant increase in net loss and revenue decline are concerning, they are largely a result of aggressive R&D spending on pivotal Phase 3 trials and the accounting treatment of prior license agreements. The completion of enrollment for wet AMD trials and promising preclinical data for DURAVYU are strong clinical positives. The recent $162.1 million capital raise provides a crucial cash runway into Q4 2027, de-risking near-term liquidity. However, this also comes with shareholder dilution. The ongoing DOJ subpoena adds a layer of uncertainty, though management believes it will not be material. Given the substantial investment, clinical progress, and extended runway, but balanced against increased losses, dilution, and regulatory overhang, a 'hold' recommendation is appropriate. Investors should await the mid-2026 Phase 3 wet AMD data readout for a clearer picture of DURAVYU's commercial potential.

Keywords

EyePoint Pharmaceuticals, EYPT, DURAVYU, wet AMD, diabetic macular edema, DME, Phase 3 clinical trials, retinal diseases, ophthalmology, biotechnology, pharmaceuticals, VEGF, tyrosine kinase inhibitor, Durasert E, equity financing, SEC filing, 10-Q, clinical development, R&D expenses, net loss, liquidity, DOJ subpoena